#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy

Data ReadoutMixedNeutral

AI Analysis

Summary

CRISPR Therapeutics presented early-stage data for its lipid-lowering gene editing therapy at ESC26, showing mixed durability results one year post-dosing, with the company planning to pursue higher doses.

Clinical Trial Data

Phase

early-stage

Outcome Details

gene editing candidate showed mixed durability results a year after patient dosing

Importance:5/10

Sentiment:

0.00

gene editingCRISPRlipid loweringdurabilitycardiology

Related Companies

$CRSP

Read the original article

Published by Endpoints News on August 28, 2026 2:30 PM

Read Original